Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Kennedy Institute are part of a UK-wide consortium that has been awarded a £644K BBSRC Network Grant to establish the Microbiome Innovation Network (Microbiome-Net).

Microbiome with microbiota

Together with researchers from the Microbiome Innovation Centre at the University of Liverpool, the National Biofilms Innovation Centre, the Quadram Institute, and Nottingham Trent University, Microbiome-Net aims to strengthen microbiome research and drive its application to some of the world's most pressing health and environmental challenges.

The three-year programme is Co-Directed by Professor Jo Fothergill, Professor of Medical Microbiology and Director of the Microbiome Innovation Centre at the University of Liverpool and Professor Jo Slater-Jefferies, CEO at the National Biofilms Innovation Centre.

Microbiome science is unlocking transformative solutions for global challenges, from health and antimicrobial resistance to food security and climate change. Microbiomes are the unique communities of microorganisms in our bodies and environments, and they influence everything from human wellbeing to agricultural productivity. The UK stands at the forefront of innovation, with sectors like healthcare, nutrition, personal care, and agriculture poised to benefit. Global markets for microbial bioproducts, such as probiotics and agricultural biologicals, are booming, valued at $71 billion and $16 billion respectively. Yet, progress can be slowed by fragmented research and limited collaboration between academia and industry. Bridging these gaps is key to unleashing the full potential of microbiome innovation.

 

Read the full story on the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences website.

Similar stories

Arthritis origins may begin before birth, study finds

Researchers at the Kennedy Institute have discovered that some joints may be more susceptible to inflammatory arthritis before birth, offering new insight into why rheumatoid arthritis attacks particular joints while sparing others.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Natural compound may help boost vaccine responses in older adults

Researchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have found that a naturally occurring compound called spermidine may help improve vaccine responses in some older adults by reducing signs of immune system ageing.

Researchers uncover hidden mechanism behind a major cancer therapy target

Kennedy researchers have revealed how one of the immune system's most important regulatory pathways operates at the earliest moments of T cell activation, providing new insights that could help improve cancer immunotherapy.

Major MRC funding for Irina Udalova to unravel neutrophil behaviour across immune pathologies

Prof Irina Udalova has received a programme grant of £2.7M from the Medical Research Council (MRC) to investigate how neutrophils – a type of white blood cell that forms the body’s first line of defence – adapt their behaviour to tissue requirements and contribute to immune diseases, leading to the development of a new class of neutrophil-targeted therapeutics.

Researchers find clue to how Sjögren’s disease persists

A new study has found that a protein TRIM21 linked to Sjögren’s disease may be fuelling the condition in an unexpected way. Researchers at the Kennedy Institute of Rheumatology have discovered that during a specific type of cell death, TRIM21 is released and combines with antibodies to overstimulate the immune system, potentially maintaining the symptoms of Sjögren’s disease.

Similar stories

Arthritis origins may begin before birth, study finds

Researchers at the Kennedy Institute have discovered that some joints may be more susceptible to inflammatory arthritis before birth, offering new insight into why rheumatoid arthritis attacks particular joints while sparing others.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Natural compound may help boost vaccine responses in older adults

Researchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have found that a naturally occurring compound called spermidine may help improve vaccine responses in some older adults by reducing signs of immune system ageing.

Researchers uncover hidden mechanism behind a major cancer therapy target

Kennedy researchers have revealed how one of the immune system's most important regulatory pathways operates at the earliest moments of T cell activation, providing new insights that could help improve cancer immunotherapy.

Major MRC funding for Irina Udalova to unravel neutrophil behaviour across immune pathologies

Prof Irina Udalova has received a programme grant of £2.7M from the Medical Research Council (MRC) to investigate how neutrophils – a type of white blood cell that forms the body’s first line of defence – adapt their behaviour to tissue requirements and contribute to immune diseases, leading to the development of a new class of neutrophil-targeted therapeutics.

Researchers find clue to how Sjögren’s disease persists

A new study has found that a protein TRIM21 linked to Sjögren’s disease may be fuelling the condition in an unexpected way. Researchers at the Kennedy Institute of Rheumatology have discovered that during a specific type of cell death, TRIM21 is released and combines with antibodies to overstimulate the immune system, potentially maintaining the symptoms of Sjögren’s disease.